Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. Chiesi Global Rare Diseases works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available.
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
We are a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient’s own cells isolated from the patient intended for treatment.
SterileCare Inc is a medical device company that develops preventative solutions to fight against the threat of serious infections. SCIs non-antibiotic antimicrobial solution significantly reduces the incidence of hospital acquired infections, including those caused by antibiotic resistant organisms, improving the quality of care to patients so they can focus on getting better.
Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing and delivering life-changing therapies to people living with rare disease.
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,153 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 343,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care.
Alnylam is the leading RNAi therapeutics company. Founded on a bold vision; turn Nobel Prize-winning science into a new class of medicines. Working tirelessly, the possibility of RNAi is now a therapeutic reality. We believe we have the potential to improve the lives of patients worldwide who are waiting for new treatment options.
Recordati Rare Diseases is part of the rare diseases business within the Recordati Group, and is dedicated to developing innovative, high-impact therapies. Our focus is on those who we believe need it most—people affected by rare diseases. They are our top priority and at the centre of everything we do.
Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science to address some of society's most challenging healthcare issues. Novartis is committed to patients living with complement-mediated kidney diseases, bringing transformative medicines that can potentially slow disease progression and extend dialysis-free life.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. For more information, go to www.bayer.com.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are no approved therapies.
Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates, including atrasentan, BION-1301 and CHK-336, and research & discovery programs, are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. To learn more, visit www.chinooktx.com.
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.